P78536 (ADA17_HUMAN) Homo sapiens (Human)

Disintegrin and metalloproteinase domain-containing protein 17 UniProtKBInterProSTRINGInteractive Modelling

824 aa; Sequence (Fasta) ; (Isoform 2); 3 identical sequences: Homo sapiens: B2RNB2; Pan troglodytes: A0A2J8NM15; Pan paniscus: A0A2R9BL62

Available Structures

29 Experimental Structures

DescriptionPDB IDOligo-stateRangeSeq id (%)Ligands
Structure of mature human ADAM17/iRhom2 sheddase complex in complex with ADAM17 prodomain Heteromer
Q6PJF5;
28-698
100ZN;CA;
Structure of human ADAM17/iRhom2 sheddase complex Heteromer
Q6PJF5;
28-698
100.0ZN;CA;
Crystal structure of the TACE-N-TIMP-3 complex Heteromer
P35625;
219-474
99.22ZN;NA;
Structure of mature human ADAM17/iRhom2 sheddase complex, conformation 2 Heteromer
Q6PJF5;
477-703
100CA;
Structure of mature human ADAM17/iRhom2 sheddase complex, conformation 1 Heteromer
Q6PJF5;
477-703
100CA;
Fully human monoclonal antibody targeting the cysteine-rich substrate-interacting region of ADAM17 … Heteromer
530-644
100
Crystal structure of the PTPN3 PDZ domain bound to the PBM TACE C-terminal peptide Heteromer
P26045;
819-824
100NA;
Crystal structure analysis 0f the TNF-a Coverting Enzyme (TACE) in complexed with Aryl-sulfonamidemonomer216-477
99.24ZN;283;
Crystal structure of TACE in complex with IK682monomer216-475
98.85ZN;541;
Crystal structure of catalytic domain of TACE with the first hydantoin inhibitor occupying the S1' …monomer216-474
98.82ZN;724;
Novel thio-based TACE inhibitors Part 2: Rational design, synthesis and SAR of thiol-contaning aryl…monomer216-474
99.23ZN;440;
Crystal structure of catalytic domain of TNF-alpha converting enzyme (TACE) with inhibitormonomer217-475
99.23ZN;IH6;
Crystal structure of catalytic domain of TACE with Thiomorpholine Sulfonamide Hydroxamate inhibitormonomer217-475
99.23ZN;4NH;
Crystal structure of catalytic domain of TACE with carboxylate inhibitormonomer218-475
98.82ZN;INN;
Crystal structure of catalytic domain of TACE with 2-(2-Aminothiazol-4-yl)pyrrolidine-Based Tartrat…monomer217-474
98.81IPA;INN;ZN;CA;
Crystal structure of catalytic domain of TACE with hydroxamate inhibitormonomer218-475
98.84ZN;INN;CIT;
Crystal structure of the catalytic domain of TACE with Isoindolinone-biphenyl-hydantoin inhibitormonomer217-474
98.84Z93;ZN;
Crystal structure of TACE in complex with JMV 390-1monomer218-475
98.82ZN;INN;
Crystal structure of TACE in complex with TAPI-2monomer218-474
98.81ZN;CA;INN;IPA;
Crystal structure of catalytic domain of TACE with tartrate-based inhibitormonomer218-474
98.82ZN;INN;
Crystal structure of catalytic domain of TACE with phenyl-pyrrolidinyl-tartrate inhibitormonomer218-474
98.81ZN;INN;IPA;
Crystal structure of the catalytic domain of TACE with Indazolinone-phenyl-hydantoin inhibitormonomer218-474
98.81ZN;727;IPA;
Crystal structure of catalytic domain of TACE with hydroxamate inhibitormonomer218-474
98.81ZN;615;INN;
Crystal structure of catalytic domain of tace with benzimidazolyl-thienyl-tartrate based inhibitormonomer218-474
98.81ZN;50X;
Crystal structure of catalytic domain of TACE with hydantoin inhibitormonomer218-474
98.82ZN;INN;IPA;
Crystal structure of catalytic domain of TACE with inhibitormonomer220-474
99.22ZN;INN;
CATALYTIC DOMAIN OF TNF-ALPHA CONVERTING ENZYME (TACE)monomer219-473
99.22ZN;INN;
Crystal Structure of TACE with Tryptophan Sulfonamide Derivative Inhibitormonomer221-474
99.21792;ZN;
The membran-proximal domain of ADAM17monomer581-642
100

1 SWISS-MODEL model

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
8snl.1.Amonomer0.7828-698
ZN;CA;100.00

1 SWISS-MODEL model built on isoform sequence

IsoformTemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
Isoform 28snl.1.Amonomer0.7928-694
ZN;CA;100.00